A patent review of IDO1 inhibitors for cancer (2023–present): an update
1. 系统已在2025-06-05 11:41:23对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
H Qiu, Y Yin, Z Qin, D Li, P Wang
Expert Opinion on Therapeutic …, 2025
Taylor & Francis
ABSTRACT Introduction Indoleamine 2, 3-dioxygenase 1 (IDO1) is a promising target in cancer immunotherapy, yet its application faces significant challenges due to complex mechanisms of action. Recent advancements in IDO1 inhibitors aim to tackle these issues, potentially paving the way for successful therapeutic development. Areas covered This review highlights patent publications (2023–2024) related to IDO1 inhibitors with potential anti-cancer applications, sourced from Espacenet and Google Scholar. Expert opinion IDO1 …
